

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/31601> holds various files of this Leiden University dissertation.

Author: Stringer, Frances

Title: Pharmacogenomics in drug development : implementation and application of PKPD model based approaches

Issue Date: 2015-01-13

Curriculum Vitae

Frances Stringer was born on August 11th 1979 in Durban, South Africa. In 1997 she completed her high school education at Hanson Upper and in the same year started her undergraduate degree at Nottingham University in England. She completed her undergraduate degree in Environmental Chemistry in 2000 and from 2000-2001 studied for a masters degree in Medicinal Chemistry and Drug Metabolism at Loughborough University.

In 2001 she started working in the pharmaceutical industry, with her first position as a Pharmacokineticist at Elan Drug Delivery in Athlone, Ireland. In 2002 she moved back to the UK to work for UCB-Celltech within the clinical assays department. From 2006-2014 she worked as a Clinical Pharmacologist for Takeda Pharmaceutical Company. Working firstly in the European headquarters in London before moving to Japan from 2010-2014. In Summer 2014, Frances joined Model Answers in Brisbane, Australia as a Pharmacometrician.

List of Publications

Stringer F, DeJongh J, Enya K, Koumura E, Danhof M, Kaku K. Evaluation of the Long-term Durability and Glycemic Control of FPG and HbA1c for Pioglitazone in Japanese Type 2 Diabetes Subjects. *Diabetes Technol Ther*. In press.

Stringer F, DeJongh J, Scott G, Danhof M. A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar. *J Clin Pharmacol*. 2014 Apr;54(4):453-61.

Stringer F, Scott G, Valbuena M, Kinley J, Nishihara M, Urquhart, R. The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent. *Eur J Clin Pharmacol*. 2013 Mar;69(3):423-30.

Stringer F, Ploeger BA, DeJongh J, Scott G, Urquhart R, Karim A, Danhof M. Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist, sipoglitazar. *J Clin Pharmacol*. 2013 Mar;53(3):256-63.

Liou S, **Stringer F**, Hirayama M. Impact of pharmaogenomics research on drug development. *Drug Metab Pharmacokinet*. 2012;27(1):2-8.

Martin P, Jones G, **Stringer F**, Wilson, I. Comparison of a beta-blocker from plasma onto a molecularly imprinted polymer with liquid-liquid extraction and solid phase extraction methods. *J Pharm Biomed Anal*. 2004 Sep 3;35(5):1231-9.

Martin P, Jones G, **Stringer F**, Wilson, I. Comparison of Normal and Reversed-Phase Solid Phase Extraction Method for Extraction of Beta-Blockers from Plasma Using Molecularly Imprinted Polymers. *Analyst*. 2003 Apr;128(4):345-50.